Gt biopharma to present at b. riley securities' virtual oncology conference

Brisbane, calif., jan. 20, 2022 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike ® protein biologic technology platform, announced today that dr. greg berk, president of r&d, chief medical officer and interim ceo will be participating in a fireside chat at the upcoming b.
GTBP Ratings Summary
GTBP Quant Ranking